Results 251 to 260 of about 399,367 (396)

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant [PDF]

, 1999
Francesco Dazzi, Richard Szydlo, John M. Goldman   +2 more
openalex   +1 more source

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Leukemia, 2016
Markus Pfirrmann, M. Baccarani, Susanne Saussele, J. Guilhot, F. Cervantes, G. Ossenkoppele, V. Hoffmann, F. Castagnetti, J. Hasford, Rüdiger Hehlmann, B. Simonsson   +10 more
semanticscholar   +1 more source

Chronic myeloid leukemia in India

Indian Journal of Medical and Paediatric Oncology, 2013
openaire   +4 more sources

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Chronic myeloid leukemia with the e13a3 atypical fusion gene: A case report. [PDF]

Oncol Lett
Zhou X, Li MR, Shan NN.
europepmc   +1 more source

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient [PDF]

, 1995
Andrew Spencer, Richard Szydlo, PA Brookes, É. Kaminski, Simon Rule, Frits van Rhee, K.N. Ward, G Hale, Herman Waldmann, JM Hows   +9 more
openalex   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Real-World Evidence of Treatment-Free Remission Strategies and Outcomes in Chronic Myeloid Leukemia. [PDF]

Cancers (Basel)
Bourne G, Diebold K, Bascug G, Knapp J, Espinoza-Gutarra M, Vachhani P, Bachiashvili K, Rangaraju S, Mohty R, Bhatia R, Jamy O.   +10 more
europepmc   +1 more source

Randomized Study on Hydroxyurea Alone Versus Hydroxyurea Combined With Low-Dose Interferon-α2b for Chronic Myeloid Leukemia [PDF]

, 1998

openalex   +1 more source

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Nature Network Boston, 2017
Alice Giustacchini, S. Thongjuea, Nikolaos Barkas, P. Woll, B. Povinelli, Christopher A. G. Booth, P. Sopp, Ruggiero Norfo, A. Rodriguez-Meira, N. Ashley, Lauren Jamieson, P. Vyas, K. Anderson, Å. Segerstolpe, H. Qian, U. Olsson‐Strömberg, S. Mustjoki, R. Sandberg, S. Jacobsen, A. Mead   +19 more
semanticscholar   +1 more source